Furthermore, we found other pleiotropic genes as drug targets for lung and GIT diseases, such as pralsetinib targeting DDR1 for the treatment of non-small cell lung cancer and trimebutine targeting CACNA1D for the treatment of IBS. The gene discussed is DDR1; the disease is irritable bowel syndrome.